NEW YORK/LOS ANGELES (Reuters) - Shocked by the rapid adoption of a new $84,000 hepatitis C treatment, U.S. health insurers are trying to make sure they aren't blindsided by other drugs being developed and are looking for ways to limit their use from the day they are launched. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/qi1FjSIRxdA/story01.htm
Read More
No comments:
Post a Comment